By abhat@reaganud… on
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=CanSino&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=c&recrs=d&recrs=f&recrs=k
Sponsor
CanSino Biologics
COVID-19 Information

CanSinoBIO’s Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in China - The vaccine candidate is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform. Results from preclinical animal studies of “Ad5-nCoV” show that the vaccine candidate can induce strong immune response in animal models. The preclinical animal safety studies demonstrated a good safety profile.

A Phase I Clinical Trial in 18-60 Adults

Stage
Phase 1
Company Type
Vaccine